Business Context and Reporting Period
CG Oncology, Inc. furnished this Form 8-K on May 24, 2024, under Regulation FD and Item 8.01 to announce final results from its Phase 2 CORE-001 trial. The study evaluated cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ. The data were scheduled for presentation at the ASCO 2024 Annual Meeting.
The Company also disclosed an updated corporate presentation on its investor relations website. The filing is not a periodic financial report.
Key Clinical and Operating Metrics
- Trial design: Phase 2, single-arm, open-label study involving 35 patients treated after disease resection.
- Complete response rate: 57% at 12 months, or 20 of 35 patients, with a 95% confidence interval of 40% to 73%.
- Complete response at any time: 83%, or 29 of 35 patients, with a 95% confidence interval of 70% to 95%.
- Complete response at 24 months: 54%, or 19 of 35 patients, with a 95% confidence interval of 37% to 71%.
- Durability: Of the 20 patients in complete response at 12 months, 19, or 95%, maintained the response for an additional 12 months. Median duration of response had not been reached and exceeded 21 months.
- Kaplan-Meier estimates: Estimated complete response rates were 77.3% at 12 months and 69.6% at 24 months.
- Progression-free survival: 100% at 24 months; no patients had progressed to muscle-invasive or metastatic disease.
- Cystectomy-free survival: 80% at 24 months for the overall population and 100% at 24 months among patients achieving complete response.
- Safety: Treatment-related adverse events were described as consistent with the individual agents, with no synergistic toxicity observed.
- Financial metrics: The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement amounts.
Material Changes Versus the Prior Comparable Period
The filing does not provide a prior-period financial comparison. Relative to previously reported CORE-001 data, the Company disclosed updated final results, including 24-month complete response, progression-free survival, cystectomy-free survival, and response durability information.
Guidance, Outlook, Risks, and Unusual Items
CG Oncology stated that the CORE-001 results support further investigation of cretostimogene in combination with checkpoint inhibitors and that the findings are planned to inform the CORE-008 trial in high-risk non-muscle-invasive bladder cancer.
The reported data remain subject to additional audit and verification, and further patient data or analyses could produce materially different conclusions. Risks include unexpected adverse effects, inadequate efficacy, failure of clinical results to predict future outcomes, and the possibility that development, regulatory approval, or commercialization may not occur. The filing also contains customary forward-looking statement disclaimers.
The trial was conducted under a clinical collaboration and supply agreement with Merck, known as MSD outside the United States and Canada.
Investor Verification Checklist
- Verify the final CORE-001 data and statistical analyses presented at the ASCO 2024 Annual Meeting.
- Review the size and composition of the 35-patient intention-to-treat population and the confidence intervals around response rates.
- Assess the durability of complete responses, including the basis for the reported duration of response exceeding 21 months.
- Review adverse-event details and treatment discontinuations rather than relying only on the summary statement regarding lack of synergistic toxicity.
- Confirm the design, timing, and regulatory status of the planned CORE-008 trial.
- Review the Company’s latest periodic filings for cash resources, operating losses, liquidity runway, financing needs, and other financial risks not addressed in this Form 8-K.